HealthPlix secures $13.5 mn in Series B round led by Lightspeed

Bengaluru-headquartered electronic medical record (EMR) provider HealthPlix Technologies on Wednesday said it has raised $13.5 million (about Rs 99.2 crore) in a Series B round led by Lightspeed. 

The round also saw participation from returning investors -- JSW Ventures, Kalaari and Chiratae, according to a statement. 

HealthPlix will use the capital to grow its doctor base in existing geographies, as well as add new towns and medical specializations said the statement. 

Founded in 2014 by Prasad Basavaraj, Raghuraj Sunder Raju and Sandeep Gudibanda, HealthPlix has so far raised $22.76 million in equity including the current round, according to data sourced from VCCEdge. The company last raised $6 million in an equity round in June 2020 from JSW Ventures and others.  

The platform provides additional features on the EMR services including appointment scheduling and billing for doctors, SMS and app based engagement for patients, generating Medical Council of India compliant prescriptions and easy access to patient history. 

“We are doubling down our efforts to help doctors provide in-person or remote consultation to their patients using the same digital platform seamlessly. Doctors using HealthPlix save time and get a unified view of their patient’s disease journey which aids their treatment decisions,” Raghuraj Sunder Raju, cofounder at HealthPlix, said. 

HealthPlix claims to serve more than 12 million unique patients and support over 60,000 consultations daily across 15 specialties. It provides a bridge between doctors to interact with patients, hospitals, diagnostic laboratories, pharmaceutical and equipment manufacturers as well as insurers.  

“What sets HealthPlix apart is its doctor-first B2B approach. Doctors are the most influential decision makers in healthcare. We believe whichever platform wins their trust will have the sole right to orchestrate the entire $88 billion of healthcare spend,” Vaibhav Agrawal, partner at Lightspeed said in the statement.